Pacritinib moving forwards for myelofibrosis
Aaron Gerds, MD, MS, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the results of PAC2013 (NCT03165734), a randomized phase…
Related Articles
Adult TA-TMA: updating definitions and considering discontinuation of GvHD prophylaxis
In this video, Aldo Acosta-Medina, MD, Mayo Clinic, Rochester, MN, discusses the clinical outcomes and treatment strategies for adult transplant-associated thrombotic microangiopathy (TA-TMA). Dr Acosta-Medina…
Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more
In this discussion, Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Thomas Martin, MD,…
Moving beyond JAK inhibition in myelofibrosis – options being explored
VJHemOnc is pleased to share a feature article that explores the biology of myelodysplastic syndromes (MDS) in younger adults – a rare, yet challenging situation.
Outcomes of patients with AML in adverse cytogenetic subgroups undergoing alloSCT in first remission
Ali Bazarbachi, MD, PhD, American University of Beirut, Beirut, Lebanon, discusses a retrospective analysis assessing post-transplant outcomes of patients with acute myeloid leukemia (AML) who…
Optimizing conditioning regimens prior to autoSCT or alloSCT for lymphoma
In this video, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the current landscape of conditioning regimens for…
Community Focus Archives | VJHemOnc
Intended for community physicians, this channel aims to inform clinical practice through expert interviews from major international congresses. The diagnosis, treatment and management of patients…
APOE2 as a risk factor for adverse post-transplant outcomes in AML
Julian Ronnacker, MD, University of Münster, Münster, Germany, discusses the impact of APOE2 on post-transplant outcomes in patients with acute myeloid leukemia (AML). The study…
The relationship between CHIP & MBL with the risk of progression to lymphoid/myeloid malignancies
Susan Slager, PhD, Mayo Clinic, Rochester, MN, comments on the findings of a study examining the relationship between monoclonal B-cell lymphocytosis (MBL) and clonal hematopoiesis…
Looking forward to the upcoming COMy 2025 meeting
In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his excitement about the upcoming 11th World Congress on Controversies in Multiple Myeloma…
Targeting heme-regulated inhibitor kinase in MDS-RS and sickle cell disease
Vera Adema, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of targeting heme-regulated inhibitor (HRI) kinase to improve aberrant…